Dividend stocks remain appealing even to wealthy investors who don't rely on income. AbbVie, Johnson & Johnson, and Pfizer are highlighted as strong options for dividend-seeking investors. AbbVie offers a forward dividend yield of nearly 3% and a 52-year streak of increases, appealing to income and value investors with its low PEG ratio and promising pipeline. Johnson & Johnson presents a nearly 3% yield and long-term resilience despite challenges like Medicare price negotiations. Pfizer boasts a nearly 6% dividend yield, supported by strong financials and strategic acquisitions, positioning it for future growth despite declining COVID-related revenue.
Category
🗞
NewsTranscript
00:00It's Benzinga, bringing Wall Street to Main Street.
00:02Dividend stocks remain appealing even to wealthy investors who don't rely on income.
00:06AbbVie, Johnson & Johnson, and Pfizer are highlighted as strong options for
00:10dividend-seeking investors. AbbVie offers a forward dividend yield of nearly 3 percent
00:15and a 52-year streak of increases, appealing to income and value investors with its low PEG
00:20ratio and promising pipeline. Johnson & Johnson prevents nearly 3 percent yield
00:24and long-term resilience despite challenges like Medicare price negotiations.
00:29Pfizer boasts a nearly 6 percent dividend yield, supported by strong financials
00:33and strategic acquisitions positioned for future growth despite declining COVID-related revenue.
00:38For all things money, visit Benzinga.com slash GSTV.